![Zoya Gluzman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Zoya Gluzman
No más puestos en curso
Perfil
Zoya Gluzman worked as a Principal at VESSL Therapeutics Ltd.
and as a Chief Technology Officer at GeneGrafts Ltd.
She holds an MBA and a doctorate degree from Technion-Israel Institute of Technology.
Antiguos cargos conocidos de Zoya Gluzman.
Empresas | Cargo | Fin |
---|---|---|
VESSL Therapeutics Ltd.
![]() VESSL Therapeutics Ltd. Medical SpecialtiesHealth Technology VESSL Therapeutics Ltd. develops cell-based therapies for large patient populations. Its solutions include MultiGeneAngio fo Peripheral Artery Disease and MultiGeneGraft for end-stage renal disease. The company was founded in August 2000 by Moshe Y. Flugelman and Basil S. Lewis and is headquartered in Haifa, Israel. | Corporate Officer/Principal | - |
GeneGrafts Ltd.
![]() GeneGrafts Ltd. BiotechnologyHealth Technology GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel. | Director Técnico/Científico/I+D | - |
Formación de Zoya Gluzman.
Technion-Israel Institute of Technology | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
GeneGrafts Ltd.
![]() GeneGrafts Ltd. BiotechnologyHealth Technology GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel. | Health Technology |
VESSL Therapeutics Ltd.
![]() VESSL Therapeutics Ltd. Medical SpecialtiesHealth Technology VESSL Therapeutics Ltd. develops cell-based therapies for large patient populations. Its solutions include MultiGeneAngio fo Peripheral Artery Disease and MultiGeneGraft for end-stage renal disease. The company was founded in August 2000 by Moshe Y. Flugelman and Basil S. Lewis and is headquartered in Haifa, Israel. | Health Technology |
- Bolsa de valores
- Insiders
- Zoya Gluzman